Document is current
Any future updates will be listed below
-
Authors
Bigley, Tarin M.
Xiong, Monica
Ali, Muhammad
Chen, Yun
Wang, Chao
Serrano, Javier Remolina
Eteleeb, Abdallah
Harari, Oscar
Yang, Liping
Patel, Swapneel J.
Cruchaga, Carlos
Yokoyama, Wayne M.
Holtzman, David M. https://orcid.org/0000-0002-3400-0856
-
Funding
Funding for this research was provided by:
national institutes of health (T32AI106688-07, T32AR007279-40, P01AG003991, P30 AG066444, RF1AG053303, RF1AG058501, U01AG058922, R01 AG057777, R01AG047644, R01 NS090934)
national institute on aging (AG062027)
foundation for the national institutes of health (R01AG044546)
foundation for barnes-jewish hospital
- License Information
-
More Information
Article History
Received: 8 July 2021
Accepted: 22 December 2021
First Online: 15 January 2022
Declarations
:
: All participants gave prospective postmortem written consent for their brains to be used for research.
: Not applicable.
: D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. C2N Diagnostics has licensed certain anti-tau antibodies to AbbVie for therapeutic development. D.M.H. is on the scientific advisory board of Denali, Genentech, and Cajal Neurosciences and consults for Eli Lilly. The lab of D.M.H. receives research grants from the National Institutes of Health, Cure Alzheimer’s Fund, Tau Consortium, the JPB Foundation, Good Ventures, C2N Diagnostics, NextCure, Novartis, and Denali. C.C. receives research support from Biogen, EISAI, Alector and Parabon. C.C. is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare. All other authors declare that they have no competing interests.
